| 
			
			 With Britain set to leave the European Union within weeks, Pinder 
			Sahota at the world's biggest insulin maker Novo Nordisk, and 
			Sanofi's Hugo Fry have rebuilt operations to withstand the most 
			turbulent of events. 
 The two companies told Reuters they had spent millions of pounds, 
			which they cannot recoup, stockpiling millions of packets of insulin 
			- used to treat diabetes - inside Britain and building new shipping 
			and air freight routes.
 
 Their plans, formulated over three years, show the lengths companies 
			across the continent are having to go to overhaul long-standing 
			supply chains that may not survive Britain's biggest trade upheaval 
			in half a century.
 
 "There is nothing comparable to this," Novo Nordisk's UK General 
			Manager Sahota told Reuters of the Danish company's preparation. 
			"It's unprecedented from a logistics point of view. We're preparing 
			for the worst-case scenario, the most extreme."
 
			
			 
			
 With two Brexit deadlines already been and gone, Prime Minister 
			Boris Johnson has vowed to take Britain out of the EU with or 
			without a deal by Oct. 31 - increasing the chance of a sudden 
			departure that brings trade tariffs and customs checks with the 
			continent for the first time in decades.
 
 The government's own planning shows that, in a worst-case scenario, 
			lorries seeking to enter Europe at the French port of Calais could 
			face delays of two-and-a-half days, creating supply disruptions that 
			could last for months.
 
 That poses a real risk for the pharmaceutical industry which imports 
			37 million packs of drugs from Europe a month. According to the 
			government, three-quarters come via that route.
 
 While Britain's GSK and AstraZeneca are world leaders in respiratory 
			and cardiovascular treatments, Britain's insulin is imported.
 
 "In the case of pharmaceuticals, you can't just throw things onto a 
			boat or a lorry, you have to test and validate these routes into the 
			country," Fry told Reuters in his office to the west of London, 
			adding they had backups to their backup plans.
 
 Both Sanofi and Novo Nordisk have reserved space on ferries going 
			the longer route to eastern English ports to avoid the main 
			Calais-Dover crossing if needed, and also air freight if required.
 
 "We anticipate that route is going to become congested so what we've 
			done is open up other routes," said Sahota. "So two other routes 
			that we've opened up are Denmark to Immingham (in north-east 
			England) and Netherlands to Immingham."
 
 SKY-HIGH STOCKPILES
 
 Novo Nordisk, Britain's biggest insulin supplier, has tripled its 
			warehouse capacity to hold 18 weeks' worth of stock - 3.8 million 
			packs that piled high would stand 12 times the height of the London 
			Shard skyscraper.
 
			
            [to top of second column] | 
            
			 
			Eli Lilly of the United States and France's Sanofi, the country's 
			second and third-biggest suppliers, have similar stockpiles. 
			Frustration is growing that while they dedicate huge resources to 
			such preparation, they are spending less time on their normal jobs.
 "When we're doing this, we're not doing other stuff," Fry said. 
			"We're not working on projects that will bring our most innovative 
			products to the market.
 
 "Although we are happy to do it, it is starting to weigh on our 
			balance sheet, on our logistics, keeping all this additional stock 
			in the country. It's not an ideal situation."
 
			The companies are confident they will be able to guarantee the 
			British supply of insulin to the around 1 million diabetes patients 
			who need it.
 But some patients like Georgina from London, who was diagnosed with 
			Type 1 diabetes more than 30 years ago, have become increasingly 
			alarmed as the chances have grown of Britain leaving the EU without 
			a deal to govern their trading relationship.
 
 "For me, I can't tell you how worried I am about that. It's 
			life-threatening for me," she said, declining to give her last name. 
			She added that she also worried about older patients she encountered 
			at clinics.
 
 The British government is organising a regular freight service 
			reserved just for drugs as part of its preparations alongside 
			industry for Brexit on Oct. 31.
 
 "We are doing everything we can to help ensure the supply of 
			medicines and medical products remains uninterrupted, including 
			insulin," said the department of health and social care.
 
 The two drug companies did not say how much their Brexit 
			preparations had cost, beyond many millions of pounds. With fixed 
			contracts with Britain's health service, they cannot raise prices.
 
 Both Fry and Sahota have had to delve into arcane areas of 
			transport.
 
 As part of their planning, for example, they have had to factor in 
			how many drivers are needed to avoid breaking legally mandated rest 
			laws, how long refrigerated lorries can operate in one stretch, and 
			what happens in the event of fuel shortages.
 
 "We're doing everything we can," said Fry. "I know more about ferry 
			crossings now than I ever thought I would."
 
 (Editing by Guy Faulconbridge and Pravin Char)
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
			
			
			 |